Breast Cancer

New findings from E. Campora and co-authors in the area of breast cancer published

Published in Women's Health Weekly, March 5th, 2009

"Docetaxel is the most active agent for metastatic breast cancer, but the optimal treatment regimen as a single agent has yet to be defined. Two consecutive monocentric phase II trials of docetaxel in metastatic breast cancer were carried out," investigators in Imperia, Italy report.

"In Trial I, 36 patients received docetaxel 35 mg/m(2) weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m(2) day 1 every 21 days. Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial H. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2009-03-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry